ATE540676T1 - Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs - Google Patents

Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs

Info

Publication number
ATE540676T1
ATE540676T1 AT08749545T AT08749545T ATE540676T1 AT E540676 T1 ATE540676 T1 AT E540676T1 AT 08749545 T AT08749545 T AT 08749545T AT 08749545 T AT08749545 T AT 08749545T AT E540676 T1 ATE540676 T1 AT E540676T1
Authority
AT
Austria
Prior art keywords
egfr
inhibitors
prostate cancer
metastatic prostate
treatment
Prior art date
Application number
AT08749545T
Other languages
English (en)
Inventor
Anne Hansen Ree
Ase Bratland
Pieter Jacob Boender
Robby Ruijtenbeek
Original Assignee
Rikshospitalet Radiumhospitalet Hf
Pamgene Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rikshospitalet Radiumhospitalet Hf, Pamgene Bv filed Critical Rikshospitalet Radiumhospitalet Hf
Application granted granted Critical
Publication of ATE540676T1 publication Critical patent/ATE540676T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08749545T 2007-04-13 2008-04-11 Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs ATE540676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700547 2007-04-13
PCT/EP2008/054432 WO2008125633A2 (en) 2007-04-13 2008-04-11 Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer

Publications (1)

Publication Number Publication Date
ATE540676T1 true ATE540676T1 (de) 2012-01-15

Family

ID=39144274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08749545T ATE540676T1 (de) 2007-04-13 2008-04-11 Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs

Country Status (4)

Country Link
US (1) US20100203043A1 (de)
EP (1) EP2157971B1 (de)
AT (1) ATE540676T1 (de)
WO (1) WO2008125633A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
WO2012155063A1 (en) * 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2780010A1 (de) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Kombinationstherapie aus hsp90-inhibitoren mit braf-inhibitoren
EP2798085B1 (de) 2011-12-30 2018-01-24 Quest Diagnostics Investments Incorporated Aptamere und diagnostische verfahren zum nachweis des egf-rezeptors
JP2015527630A (ja) 2012-06-06 2015-09-17 ザ プロクター アンド ギャンブルカンパニー ヘア／頭皮ケア組成物向け化粧剤の同定システム及び方法
WO2019197683A1 (en) * 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
AU2002315306B2 (en) * 2001-05-08 2007-05-17 Merck Patent Gmbh Combination therapy using anti-EGFR antibodies and anti-hormonal agents
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2006052249A1 (en) * 2004-11-08 2006-05-18 The Regents Of The University Of California Methods involving the pi3k/akt in gliomas and prostate cancers

Also Published As

Publication number Publication date
EP2157971B1 (de) 2012-01-11
WO2008125633A2 (en) 2008-10-23
EP2157971A2 (de) 2010-03-03
US20100203043A1 (en) 2010-08-12
WO2008125633A3 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
WO2008125633A3 (en) Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
DE602006021142D1 (de) Verfahren zur behandlung von gefitinib-resistentem krebs
ATE554267T1 (de) Verfahren und systeme zur beurteilung und behandlung von zuvor frakturierten unterirdischen formationen
WO2007141280A3 (en) Proteins
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
UA106771C2 (uk) Моноклональні антитіла до прогастрину та їх використання
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
EP1991274A4 (de) Verfahren zur behandlung, prophylaxe und diagnose von knochenerkrankungen
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
ATE502944T1 (de) 2-amino-5,7-dihydro-6h-pyrroloä3,4- düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
EA201001749A1 (ru) Способ лечения недифференцированного артрита
ATE431426T1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
BRPI0818437B8 (pt) anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
TW200626900A (en) Wnt proteins and detection and treatment of cancer
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
EA200701978A1 (ru) Способ получения опиоидных модуляторов
ATE555131T1 (de) Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
MY155340A (en) Use of cathepsin c
WO2007101063A3 (en) Treatment of development-related disorders
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
WO2008115478A3 (en) Method of cancer detection and treatment